Product

Hikma receives FDA approval for Etomidate Injection

London, 9 March 2016 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody’s / BB+ S&P, both stable), the fast growing multinational pharmaceutical group, announces that its abbreviated new drug application (“ANDA”) for Etomidate Injection USP, 2mg/mL (10 mL and 20 mL single-dose vials) , has been approved by the U.S. Food and Drug Administration (“FDA”).

Etomidate Injection is an anaesthetic agent used for the induction of general anaesthesia and sedation. According to IMS Health, sales of Etomidate Injection in the US market were approximately $11.2 million for the 12 months ending January 2016.